Hepatitis C infection, treatment regimens, and thyroid function abnormalities

Endocrinologist

Volumn 17, Issue 4, 2007, Pages 231-235

  Tran, Huy A ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

interferon; HCV; Hypothyroidism; Ribavirin; Thyrotoxicosis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; LIOTHYRONINE; PEGINTERFERON; RIBAVIRIN; THYROTROPIN; THYROXINE; TUMOR NECROSIS FACTOR;

AUTOIMMUNE DISEASE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; EPIDEMIC; GENETIC PREDISPOSITION; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; IMMUNOMODULATION; MONOTHERAPY; MULTIPLE SCLEROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PREGNANCY; PREVALENCE; REVIEW; SMOKING; THYROID DISEASE; THYROID FUNCTION; THYROTOXICOSIS;

EID: 34547677791     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3180dc91d3     Document Type: Review

References (55)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(3 suppl):62S-65S.
2. World Health Organization website. Available at: http://www.who.int/csr/ disease/hepatitis/whocdscsrlyo2003/en/index3. html. Accessed December 10, 2006.
3. Australia's notifiable diseases status, 2002. Annual report of the National Notifiable Diseases Surveillance System. Available at: http://www.cda.gov.au. Accessed December 10, 2006.
4. World Health Organization. Hepatitis C: global prevalence (update). Wkly Epidemiol Rec. 1999;74:425-427.
5. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
6. Wilson LE, Widman D, Dikman SH, et al. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002;32:163-173.
7. Demers LM, Spencer CA. Laboratory support for the diagnosis and monitoring of thyroid disease, 2003. Available at: www.nacb.org/lmpg/ thyroid_lmpg_pub.htm. Accessed December 10, 2006.
8. Carella C, Mazziotti G, Amato G, et al. Interferon-α-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656-3661.
9. Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease. Thyroid. 2003;13:547-551.
10. Corssmit EPM, Heyligenberg R, Endert E, et al. Acute effects of interferon-alpha administration on thyroid hormone metabolism in health men. J Clin Endocrinol Metab. 1995;80:3140-3144.
11. Tran HA, Jones TL, Batey RG. The spectrum of thyroid disease treated with alpha-2-beta interferon and ribavirin in an Australian population. BMC Endocr Disord. 2005;5:8.
12. Lloyd AR, Jagger E, Post JJ, et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol. Advance online publication, 28 November 2006.
13. Tilg H. New insights into the mechanisms of interferon alpha: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 1997;112:1017-1021.
14. Caraccio N, Guannini R, Cuccato S, et al. Type I interferon modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab. 2005;90:1156-1162.
15. Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab. 2001;86:3525-3532.
16. Tran HA, Attia J, Jones TL, et al. Pegylated interferon-alpha-2-beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha-2-beta in a hepatitis C population: meta-analysis. J Hepatol Gastroenterol. Advance online publication, 1 December 2006.
17. Minelli R, Braverman LE, Biuberti T, et al. Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment. Clin Endocrinol (Oxf). 1997;47:357-361.
18. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrin Rev. 2003;24:694-717.
19. Kontorinis N, Garas GM, Young J, et al. Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Intern Med J. 2003;33:500-504.
20. Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab. 1995;80:922-926.
21. Ward LD, Bing-You GR. Autoimmune thyroid dysfunction induced by interferon-alfa treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract. 2001;7:52-58.
22. Chan WB, Chow CC, Cockram SC. Interferon alpha treatment and endocrine disease. J R Soc Med. 2003;96:484-485.
23. Hsieh M-C, Yu M-L, Chuang W-L, et al. Virologic factors related to interferon-α-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000;142:341-347.
24. Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002;251:400-406.
25. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158:1445-1448.
26. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab. 2001;86:1925-1929.
27. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez F, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin Endocrinol. 1996;44:635-642.
28. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am. 1997;26:189-218.
29. Wong V, Fu Xi-Li A, George J, et al. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol. 2002;56:793-798.
30. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon-α-2β and ribavirin therapy in men with chronic hepatitis C. Arch Intern Med. 2004;164:2371-2376.
31. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117:10-13.
32. Lin YQ, Wang X, Murthy MS, et al. Life-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic hepatitis C. Endocr Pract. 2005;11:135-139.
33. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283-291.
34. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995;132:587-593.
35. Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection. Arch Intern Med. 2005;165:2206-2212.
36. Russe MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719.
37. Hadziyannis SJ, Sette H, Morgan HR, et al. Peginterferon-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
38. Myers RP, Benhamou Y, Bochet M, et al. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75-79.
39. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347;13:975-982.
40. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-1028.
41. Moreno L, Quereda C, Moreno A, et al. Pegylated interferon 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004;18:67-73.
42. Tran HA. The uncertain natural history of thyrotoxic patient treated with combination interferon alfa-2β and ribavirin. Arch Intern Med. 2005;165:1072.
43. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
44. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano Survey. J Clin Endocrinol Metab. 1999;84:561-566.
45. Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol. 1995;43:55-68.
46. Ganne-Carrie N, Medini A, Coderc E, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun. 2000;14:189-193.
47. Baudin E, Marcellin P, Pouteau M, et al. Reversibility or thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol. 1993;39:657-661.
48. Marcellin P, Pouteau M, Benhamou J-P. Hepatitis C viral infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995;22:364-369.
49. Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinol Metab Clin North Am. 2001;30:315-337.
50. Salabe-Lotz H, Salabe GB. Population survey of thyroid autoimmunity in Italy: three year follow up. Thyroidology. 1990;2:107-112.
51. Huang MJ, Tsai SL, Huang BY, et al. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol. 1999;50:503-509.
52. Rocco A, Gargano S, Provenzano A, et al. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neurol Endocrinol Lett. 2001;22:39-44.
53. Piquer S, Hernandez C, Enriquez J, et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med. 2001;137:38-42.
54. Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab. 1999;84:90-97.
55. Flynn RWV, MacDonald TM, Morris AD, et al. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab. 2004;89:3879-3884.